Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study

J. Kučera, K. Strnadová, B. Dvořánková, L. Lacina, I. Krajsová, J. Štork, H. Kovářová, HK. Skalníková, P. Vodička, J. Motlík, P. Dundr, K. Smetana, O. Kodet,

. 2019 ; 42 (5) : 1793-1804. [pub] 20190917

Language English Country Greece

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc20005874

Grant support
NV16-30954A MZ0 CEP Register
NV16-30954A MZ0 CEP Register

The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key factor in cancer biology, with an impact on proliferation, invasion, angiogenesis and metastatic spread, as well as acquired therapy resistance. Multiple bioactive molecules playing cooperative roles promote the chronic inflammatory milieu in tumours, making inflammation a hallmark of cancer. This specific inflammatory setting is evident in the affected tissue. However, certain mediators can leak into the systemic circulation and affect the whole organism. The present study analysed the complex inflammatory response in the sera of patients with MM of various stages. Multiplexed proteomic analysis (Luminex Corporation) of 31 serum proteins was employed. These targets were observed in immunohistochemical profiles of primary tumours from the same patients. Furthermore, these proteins were analysed in MM cell lines and the principal cell population of the melanoma microenvironment, cancer‑associated fibroblasts. Growth factors such as hepatocyte growth factor, granulocyte‑colony stimulating factor and vascular endothelial growth factor, chemokines RANTES and interleukin (IL)‑8, and cytokines IL‑6, interferon‑α and IL‑1 receptor antagonist significantly differed in these patients compared with the healthy controls. Taken together, the results presented here depict the inflammatory landscape that is altered in melanoma patients, and highlight potentially relevant targets for therapy improvement.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005874
003      
CZ-PrNML
005      
20200526134321.0
007      
ta
008      
200511s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2019.7319 $2 doi
035    __
$a (PubMed)31545456
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kučera, Jan $u Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic.
245    10
$a Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study / $c J. Kučera, K. Strnadová, B. Dvořánková, L. Lacina, I. Krajsová, J. Štork, H. Kovářová, HK. Skalníková, P. Vodička, J. Motlík, P. Dundr, K. Smetana, O. Kodet,
520    9_
$a The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key factor in cancer biology, with an impact on proliferation, invasion, angiogenesis and metastatic spread, as well as acquired therapy resistance. Multiple bioactive molecules playing cooperative roles promote the chronic inflammatory milieu in tumours, making inflammation a hallmark of cancer. This specific inflammatory setting is evident in the affected tissue. However, certain mediators can leak into the systemic circulation and affect the whole organism. The present study analysed the complex inflammatory response in the sera of patients with MM of various stages. Multiplexed proteomic analysis (Luminex Corporation) of 31 serum proteins was employed. These targets were observed in immunohistochemical profiles of primary tumours from the same patients. Furthermore, these proteins were analysed in MM cell lines and the principal cell population of the melanoma microenvironment, cancer‑associated fibroblasts. Growth factors such as hepatocyte growth factor, granulocyte‑colony stimulating factor and vascular endothelial growth factor, chemokines RANTES and interleukin (IL)‑8, and cytokines IL‑6, interferon‑α and IL‑1 receptor antagonist significantly differed in these patients compared with the healthy controls. Taken together, the results presented here depict the inflammatory landscape that is altered in melanoma patients, and highlight potentially relevant targets for therapy improvement.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a krevní proteiny $x analýza $7 D001798
650    _2
$a fibroblasty asociované s nádorem $x metabolismus $7 D000072645
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chemokiny $x krev $7 D018925
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x krev $x metabolismus $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prognóza $7 D011379
650    _2
$a proteomika $x metody $7 D040901
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Strnadová, Karolína $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Dvořánková, Barbora $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Lacina, Lukáš $u Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Krajsová, Ivana $u Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Štork, Jiří $u Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Kovářová, Hana $u Laboratory of Applied Proteome Analyses and Research Centre PIGMOD, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Liběchov 277 21, Czech Republic.
700    1_
$a Skalníková, Helena Kupcová $u Laboratory of Applied Proteome Analyses and Research Centre PIGMOD, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Liběchov 277 21, Czech Republic.
700    1_
$a Vodička, Petr $u Laboratory of Applied Proteome Analyses and Research Centre PIGMOD, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Liběchov 277 21, Czech Republic.
700    1_
$a Motlík, Jan $u Laboratory of Applied Proteome Analyses and Research Centre PIGMOD, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Liběchov 277 21, Czech Republic.
700    1_
$a Dundr, Pavel $u Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Smetana, Karel $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic.
700    1_
$a Kodet, Ondřej $u Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic.
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 42, č. 5 (2019), s. 1793-1804
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31545456 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526134317 $b ABA008
999    __
$a ok $b bmc $g 1524732 $s 1095930
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 42 $c 5 $d 1793-1804 $e 20190917 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
GRA    __
$a NV16-29032A $a NV16-30954A $p MZ0 $p MZ0
GRA    __
$a NV16-29032A $a NV16-30954A $p MZ0 $p MZ0
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options